vs

Side-by-side financial comparison of Absci Corp (ABSI) and Ametek (AME). Click either name above to swap in a different company.

Ametek is the larger business by last-quarter revenue ($2.0B vs $650.0K, roughly 3074.5× Absci Corp). Ametek runs the higher net margin — 19.9% vs -4548.0%, a 4567.9% gap on every dollar of revenue. On growth, Ametek posted the faster year-over-year revenue change (13.4% vs -2.3%). Ametek produced more free cash flow last quarter ($527.3M vs $-29.3M). Over the past eight quarters, Ametek's revenue compounded faster (7.3% CAGR vs -14.9%).

Absci Corp is a synthetic biology and AI-powered biotech firm focused on advancing next-generation biologic drug discovery and development. It delivers integrated protein engineering solutions to pharmaceutical and biopharmaceutical partners, enabling faster creation of novel antibodies, therapeutic proteins and other complex biologic candidates to address unmet global medical needs.

AMETEK, Inc. is an American multinational conglomerate and global designer and manufacturer of electronic instruments and electromechanical devices with headquarters in the United States and over 150 sites worldwide.

ABSI vs AME — Head-to-Head

Bigger by revenue
AME
AME
3074.5× larger
AME
$2.0B
$650.0K
ABSI
Growing faster (revenue YoY)
AME
AME
+15.7% gap
AME
13.4%
-2.3%
ABSI
Higher net margin
AME
AME
4567.9% more per $
AME
19.9%
-4548.0%
ABSI
More free cash flow
AME
AME
$556.6M more FCF
AME
$527.3M
$-29.3M
ABSI
Faster 2-yr revenue CAGR
AME
AME
Annualised
AME
7.3%
-14.9%
ABSI

Income Statement — Q4 2025 vs Q4 2025

Metric
ABSI
ABSI
AME
AME
Revenue
$650.0K
$2.0B
Net Profit
$-29.6M
$398.6M
Gross Margin
36.0%
Operating Margin
-4775.5%
25.3%
Net Margin
-4548.0%
19.9%
Revenue YoY
-2.3%
13.4%
Net Profit YoY
-2.0%
2.9%
EPS (diluted)
$-0.19
$1.73

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABSI
ABSI
AME
AME
Q4 25
$650.0K
$2.0B
Q3 25
$378.0K
$1.9B
Q2 25
$593.0K
$1.8B
Q1 25
$1.2M
$1.7B
Q4 24
$665.0K
$1.8B
Q3 24
$1.7M
$1.7B
Q2 24
$1.3M
$1.7B
Q1 24
$898.0K
$1.7B
Net Profit
ABSI
ABSI
AME
AME
Q4 25
$-29.6M
$398.6M
Q3 25
$-28.7M
$371.4M
Q2 25
$-30.6M
$358.4M
Q1 25
$-26.3M
$351.8M
Q4 24
$-29.0M
$387.3M
Q3 24
$-27.4M
$340.2M
Q2 24
$-24.8M
$337.7M
Q1 24
$-22.0M
$310.9M
Gross Margin
ABSI
ABSI
AME
AME
Q4 25
36.0%
Q3 25
36.3%
Q2 25
35.8%
Q1 25
36.1%
Q4 24
36.6%
Q3 24
36.0%
Q2 24
36.0%
Q1 24
34.1%
Operating Margin
ABSI
ABSI
AME
AME
Q4 25
-4775.5%
25.3%
Q3 25
-7977.2%
25.8%
Q2 25
-5293.9%
26.0%
Q1 25
-2351.9%
26.3%
Q4 24
-4477.3%
26.6%
Q3 24
-1698.7%
26.1%
Q2 24
-2104.0%
25.8%
Q1 24
-2616.7%
24.0%
Net Margin
ABSI
ABSI
AME
AME
Q4 25
-4548.0%
19.9%
Q3 25
-7594.2%
19.6%
Q2 25
-5155.0%
20.2%
Q1 25
-2234.6%
20.3%
Q4 24
-4358.3%
22.0%
Q3 24
-1610.7%
19.9%
Q2 24
-1948.8%
19.5%
Q1 24
-2447.1%
17.9%
EPS (diluted)
ABSI
ABSI
AME
AME
Q4 25
$-0.19
$1.73
Q3 25
$-0.20
$1.60
Q2 25
$-0.24
$1.55
Q1 25
$-0.21
$1.52
Q4 24
$-0.26
$1.67
Q3 24
$-0.24
$1.47
Q2 24
$-0.22
$1.45
Q1 24
$-0.22
$1.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABSI
ABSI
AME
AME
Cash + ST InvestmentsLiquidity on hand
$144.3M
$458.0M
Total DebtLower is stronger
$2.3B
Stockholders' EquityBook value
$189.4M
$10.6B
Total Assets
$216.3M
$16.1B
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABSI
ABSI
AME
AME
Q4 25
$144.3M
$458.0M
Q3 25
$152.5M
$439.2M
Q2 25
$38.0M
$619.7M
Q1 25
$47.0M
$399.0M
Q4 24
$112.4M
$374.0M
Q3 24
$38.2M
$396.3M
Q2 24
$42.9M
$396.6M
Q1 24
$58.8M
$373.8M
Total Debt
ABSI
ABSI
AME
AME
Q4 25
$2.3B
Q3 25
Q2 25
Q1 25
Q4 24
$4.0M
$2.1B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ABSI
ABSI
AME
AME
Q4 25
$189.4M
$10.6B
Q3 25
$210.3M
$10.5B
Q2 25
$173.4M
$10.4B
Q1 25
$198.8M
$10.0B
Q4 24
$179.1M
$9.7B
Q3 24
$201.3M
$9.6B
Q2 24
$221.5M
$9.3B
Q1 24
$240.1M
$9.0B
Total Assets
ABSI
ABSI
AME
AME
Q4 25
$216.3M
$16.1B
Q3 25
$245.0M
$16.2B
Q2 25
$209.9M
$15.3B
Q1 25
$232.4M
$14.9B
Q4 24
$213.6M
$14.6B
Q3 24
$235.2M
$14.8B
Q2 24
$255.5M
$14.8B
Q1 24
$274.9M
$14.9B
Debt / Equity
ABSI
ABSI
AME
AME
Q4 25
0.21×
Q3 25
Q2 25
Q1 25
Q4 24
0.02×
0.22×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABSI
ABSI
AME
AME
Operating Cash FlowLast quarter
$-29.2M
$584.3M
Free Cash FlowOCF − Capex
$-29.3M
$527.3M
FCF MarginFCF / Revenue
-4505.4%
26.4%
Capex IntensityCapex / Revenue
15.8%
2.9%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters
$-94.2M
$1.7B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABSI
ABSI
AME
AME
Q4 25
$-29.2M
$584.3M
Q3 25
$-25.0M
$440.9M
Q2 25
$-16.9M
$359.1M
Q1 25
$-21.8M
$417.5M
Q4 24
$-17.0M
$550.0M
Q3 24
$-20.7M
$487.2M
Q2 24
$-16.8M
$381.4M
Q1 24
$-17.9M
$410.2M
Free Cash Flow
ABSI
ABSI
AME
AME
Q4 25
$-29.3M
$527.3M
Q3 25
$-26.0M
$420.0M
Q2 25
$-17.1M
$329.8M
Q1 25
$-21.9M
$394.5M
Q4 24
$-17.0M
$498.3M
Q3 24
$-20.8M
$460.9M
Q2 24
$-17.2M
$360.0M
Q1 24
$382.6M
FCF Margin
ABSI
ABSI
AME
AME
Q4 25
-4505.4%
26.4%
Q3 25
-6876.5%
22.2%
Q2 25
-2883.0%
18.5%
Q1 25
-1854.5%
22.8%
Q4 24
-2554.4%
28.3%
Q3 24
-1221.6%
27.0%
Q2 24
-1352.4%
20.8%
Q1 24
22.0%
Capex Intensity
ABSI
ABSI
AME
AME
Q4 25
15.8%
2.9%
Q3 25
254.5%
1.1%
Q2 25
37.6%
1.6%
Q1 25
2.1%
1.3%
Q4 24
3.5%
2.9%
Q3 24
2.8%
1.5%
Q2 24
26.2%
1.2%
Q1 24
0.0%
1.6%
Cash Conversion
ABSI
ABSI
AME
AME
Q4 25
1.47×
Q3 25
1.19×
Q2 25
1.00×
Q1 25
1.19×
Q4 24
1.42×
Q3 24
1.43×
Q2 24
1.13×
Q1 24
1.32×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABSI
ABSI

Segment breakdown not available.

AME
AME

Transferred At Point In Time$1.1B54%
Electronic Instruments Group$620.1M31%
Transferred Over Time$294.6M15%

Related Comparisons